The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group.
B. Chauffert
Consultant or Advisory Role - Roche
L. Feuvret
No relevant relationships to disclose
F. Bonnetain
No relevant relationships to disclose
L. Taillandier
No relevant relationships to disclose
H. Taillia
No relevant relationships to disclose
D. Frappaz
No relevant relationships to disclose
R. Schott
No relevant relationships to disclose
J. Honnorat
Honoraria - Roche
Other Remuneration - Roche
M. Fabbro
No relevant relationships to disclose
I. Tennevet
No relevant relationships to disclose
F. Ghiringhelli
No relevant relationships to disclose
J. S. Guillamo
No relevant relationships to disclose
X. Durando
No relevant relationships to disclose
D. Castera
No relevant relationships to disclose
M. Frenay
No relevant relationships to disclose
C. Campello
No relevant relationships to disclose
R. Guillevin
No relevant relationships to disclose
J. Skrzypski
No relevant relationships to disclose
T. S. Dabakuyo
No relevant relationships to disclose
O. L. Chinot
Consultant or Advisory Role - Roche
Research Funding - Roche